Trial Profile
Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esophagogastric Junction or Gastric Cancer after failure of one but not more than two prior lines of systemic therapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Elisidepsin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms IMAGE
- 04 Apr 2022 This trial has been completed in France (End Date: 04 May 2021), according to European Clinical Trials Database record.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
- 23 Jun 2012 Planned number of patients changed from 118 to 126 as reported by European Clinical Trials Database.